Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Basal-like breast cancers, often with BRCA1 mutations, are typically triple-negative.
• Triple-negative breast cancers lack targeted therapy options due to absent hormone receptors and HER2/neu amplification.
• These cancers exhibit impaired DNA base-excision repair, a pathway crucial for fixing oxidative DNA damage.

Purpose of the Study:

• To investigate the therapeutic potential of elesclomol in basal-like and BRCA1-mutated breast cancers.
• To determine if defective oxidative DNA damage repair predicts sensitivity to elesclomol.
• To explore elesclomol as a novel treatment strategy for triple-negative breast cancers.

Main Methods:

• Analysis of DNA base-excision repair pathway function in BRCA1-mutated and basal-like breast cancer models.
• Assessment of cancer cell sensitivity to elesclomol, an oxidative stress-inducing agent.
• Correlation of DNA repair deficiency with treatment response to elesclomol.

Main Results:

• BRCA1-mutated and basal-like breast cancers demonstrate a compromised DNA base-excision repair pathway.
• This defective repair mechanism was found to predict sensitivity to elesclomol.
• Elesclomol effectively targets cancer cells with impaired oxidative DNA damage repair.

Conclusions:

• Defective DNA repair in basal-like and BRCA1-mutated breast cancers identifies a potential therapeutic vulnerability.
• Elesclomol shows promise as a treatment for these aggressive breast cancer subtypes.
• Treatment regimens incorporating elesclomol may benefit patients with BRCA1-mutated or basal-like breast cancers.